IVIG 10%
Biological
Kedrion S.p.A.
Total Payments
$1.4M
Transactions
123
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $949,166 | 111 | 0 |
| 2019 | $426,910 | 12 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 123 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients | Kedrion S.p.A. | $1.4M | 0 |
| Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients | Kedrion S.p.A. | $6,075 | 0 |
Top Doctors Receiving Payments for IVIG 10%
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $1.4M | 123 |
Ad
Manufacturing Companies
- Kedrion S.p.A. $1.4M
Product Information
- Type Biological
- Total Payments $1.4M
- Total Doctors 0
- Transactions 123
About IVIG 10%
IVIG 10% is a biological associated with $1.4M in payments to 0 healthcare providers, recorded across 123 transactions in the CMS Open Payments database. The primary manufacturer is Kedrion S.p.A..
Payment data is available from 2019 to 2020. In 2020, $949,166 was paid across 111 transactions to 0 doctors.
The most common payment nature for IVIG 10% is "Unspecified" ($1.4M, 100.0% of total).
IVIG 10% is associated with 2 research studies, including "A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients" ($1.4M).